De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)

被引：0
作者：
Ted A. Skolarus
Sarah T. Hawley
Daniela A. Wittmann
Jane Forman
Tabitha Metreger
Jordan B. Sparks
Kevin Zhu
Megan E. V. Caram
Brent K. Hollenbeck
Danil V. Makarov
John T. Leppert
Jeremy B. Shelton
Vahakn Shahinian
Sriram Srinivasaraghavan
Anne E. Sales
机构：
[1] VA Ann Arbor Healthcare System,VA HSR&D Center for Clinical Management Research
[2] University of Michigan Medical School,Department of Urology, Dow Division of Health Services Research
[3] University of Michigan Medical School,Department of Internal Medicine, Division of Hematology/Oncology
[4] University of Michigan Medical School,Department of Learning Health Sciences
[5] NYU Langone Medical Center,Departments of Urology and Population Health
[6] VA New York Harbor Healthcare System,Department of Urology
[7] Stanford University School of Medicine,Division of Nephrology
[8] VA Palo Alto Healthcare System,undefined
[9] VA Greater Los Angeles Healthcare System,undefined
[10] University of Michigan Medical School,undefined
[11] University of Michigan Ross School of Business,undefined
来源：
Implementation Science | / 13卷
关键词：
Castration; De-implementation; Choosing wisely; Low value care; Implementation science; Intervention; Formulary restriction; Decision-making; Behavior change; Discrete choice; Stakeholder; Androgen deprivation therapy (ADT);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 321 条
  • [1] Shahinian VB(2006)Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist J Natl Cancer Inst 98 839-845
  • [2] Kuo YF(2011)Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States Urol Oncol 29 647-653
  • [3] Freeman JL(2014)American Cancer Society prostate cancer survivorship care guidelines CA Cancer J Clin 64 225-249
  • [4] Goodwin JS(2010)Reimbursement policy and androgen-deprivation therapy for prostate cancer N Engl J Med 363 1822-1832
  • [5] Gilbert SM(2015)Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate Cancer Eur Urol 68 805-811
  • [6] Kuo YF(2014)Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer J Clin Oncol 32 1324-4840
  • [7] Shahinian VB(2017)Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer Cancer 123 4832-2131
  • [8] Skolarus TA(2007)Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2106-479
  • [9] Wolf AM(2014)EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 65 467-137
  • [10] Erb NL(2014)EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013 Eur Urol 65 124-39
12345678910